English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The bispecific antibody (bsAbs) research around the world has undergone great changes. We analyzed the global trend of bsAbs research and compared the differences in clinical research of bsAbs between China and worldwide.    Methods  BsAbs research clinical trials information was retrieved through the online open-resource clinical trial registration platform. Research information including organizations, identity numbers, locations, phases, participating centers, conditions, status, enrollment, targets, spectrums of mechanism of action (MOA), and start date was collected. Clinical trials were divided into two categories based on the attributes of pharmaceutical companies (international or China-initiated or involved).    Results  From 1997 to 2020, 272 clinical trials regarding bsAbs research were retrieved. Twenty-nine percent of the studies were contributed by companies from Chinese institutions, which followed the USA and ranked second. The clinical trials of bsAbs are mainly concentrated on phase I ( n  = 161), phase I/II ( n  = 54), and phase II ( n  = 51), and the number of phase III trials is still rare ( n  = 4). Tumor species distribution analysis shows that there are significantly higher focuses on gastric cancer ( n  = 18), esophageal/gastroesophageal junction cancer ( n  = 16), bladder cancer ( n  = 10), biliary malignant tumor ( n  = 8), nasopharyngeal cancer ( n  = 6), and thymic cancer ( n  = 2) in China. BsAbs target and spectrums of MOA analysis showed that international companies mainly focus on bsAbs with CD3-based ( n  = 63) target with MOA of T-cell redirection, while researches in China pay more attention to PD-1 ( n  = 9)/PD-L1 ( n  = 7) axises with MOA of double immune checkpoint blocking.    Conclusion  Global bsAbs research increased rapidly during the 1997 to 2020 period. The developed countries in America and Europe are leading the trend of bsAbs research. Anticancer bsAbs clinical research in China is booming and chasing after the world trend.    Supplementary Information  The online version contains supplementary material available at 10.1186/s13045-021-01126-x.

Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China